West Pharmaceutical Services (STU:WPS) Total Liabilities : €865 Mil (As of Mar. 2025)

View and export this data going back to 2016. Start your Free Trial

What is West Pharmaceutical Services Total Liabilities?

West Pharmaceutical Services's Total Liabilities for the quarter that ended in Mar. 2025 was €865 Mil.

West Pharmaceutical Services's quarterly Total Liabilities increased from Sep. 2024 (€831.62 Mil) to Dec. 2024 (€917.85 Mil) but then declined from Dec. 2024 (€917.85 Mil) to Mar. 2025 (€864.97 Mil).

West Pharmaceutical Services's annual Total Liabilities declined from Dec. 2022 (€879.71 Mil) to Dec. 2023 (€869.77 Mil) but then increased from Dec. 2023 (€869.77 Mil) to Dec. 2024 (€917.85 Mil).

West Pharmaceutical Services Total Liabilities Historical Data

The historical data trend for West Pharmaceutical Services's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

West Pharmaceutical Services Total Liabilities Chart

West Pharmaceutical Services Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Liabilities

Get a 7-Day Free Trial

772.11

865.88

879.71

869.77

917.85

West Pharmaceutical Services Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Total Liabilities	Get a 7-Day Free Trial															847.96	847.81	831.62	917.85	864.97

West Pharmaceutical Services Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

West Pharmaceutical Services's Total Liabilities for the fiscal year that ended in Dec. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	525.632	+	(271.602	+	59.401
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	34.285	+	26.931	+	0)
	=	918

Total Liabilities	=	Total Assets (A: Dec. 2024 )	-	Total Equity (A: Dec. 2024 )
	=	3479.447	-	2561.597
	=	918

West Pharmaceutical Services's Total Liabilities for the quarter that ended in Mar. 2025 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	487.197	+	(260.295	+	60.773
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	30.247	+	26.455	+	0)
	=	865

Total Liabilities	=	Total Assets (Q: Mar. 2025 )	-	Total Equity (Q: Mar. 2025 )
	=	3346.835	-	2481.867
	=	865

West Pharmaceutical Services Total Liabilities Related Terms

Thank you for viewing the detailed overview of West Pharmaceutical Services's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

West Pharmaceutical Services Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » West Pharmaceutical Services Inc (STU:WPS) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

WST:USA W2ST34:Brazil

Address

530 Herman O. West Drive, Exton, PA, USA, 19341-1147

Website

https://www.westpharma.com

West Pharmaceutical Services is based in Pennsylvania, US, and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), non-glass containment solutions, and auto-injectors for injectable drugs, which include large molecule biologics, peptides such as GLP-1 receptor agonists, and small molecule drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.